How hayfever works: The Full Evidence

In women with allergic rhinitis, does symptom severity (measured by validated TNSS and VAS scores) vary systematically across the menstrual cycle phases — follicular, ovulatory, luteal, and menstrual — and is this variation clinically meaningful relative to standard treatment effect sizes?

What the research says

No published studies have directly measured TNSS or VAS scores systematically across all four menstrual cycle phases (follicular, ovulatory, luteal, menstrual) in women with allergic rhinitis, making quantitative phase-specific conclusions impossible. Available observational and small provocation data suggest nasal symptoms — particularly congestion — are most pronounced around ovulation (estrogen peak), with some evidence of progesterone-mediated modulation in the luteal phase, but these findings rely on non-validated endpoints (rhinomanometry, rhinometry) in small samples. No direct comparison between cycle-related symptom variation magnitude and standard treatment effect sizes (e.g., TNSS reductions of 30–50% with intranasal corticosteroids) has been performed, though inferred cycle effects appear substantially smaller.

How it works

Estrogen peaks during the ovulatory phase upregulate nasal mucosal vasodilation, histamine sensitivity, and mast cell reactivity, while promoting pro-inflammatory IgE responses, thereby worsening nasal obstruction and congestion. Endogenous progesterone in the luteal phase may attenuate some of these effects, whereas aquaporin-5 regulation and mucociliary function also fluctuate hormonally across the cycle, contributing to phase-dependent changes in nasal airway patency.

---

Does the menstrual cycle affect hayfever symptom severity?

What the research says

There is limited but suggestive evidence that menstrual cycle phases influence nasal airway physiology and allergic reactivity, with estrogen peaks at midcycle associated with increased nasal mucosal hyperreactivity and skin prick test responses in women with allergic disease. A large Nordic-Baltic population study (n=3,926) demonstrated cyclical variation in respiratory symptoms, though hayfever-specific nasal symptom scores (e.g., TNSS) have not been systematically quantified across cycle phases. The overall evidence base is predominantly observational and largely focused on asthma rather than allergic rhinitis specifically, limiting firm conclusions.

How it works

Estrogen appears to promote mast cell degranulation and histamine release in a dose-dependent manner, potentially heightening nasal mucosal inflammation and hyperreactivity during the late follicular and ovulatory phases; emerging evidence also implicates cycle-dependent regulation of aquaporin-5 in nasal mucosa, affecting nasal hydration and airway patency. Progesterone in the luteal phase may exert a partial stabilizing effect on mast cells, though this remains poorly characterised in nasal tissue specifically.

---

How does oestrogen modulate mast cell degranulation and histamine release?

What the research says

Oestrogen, primarily via oestradiol (E2), enhances mast cell degranulation and histamine release in a dose-dependent manner, augmenting both spontaneous and IgE-mediated responses in rat peritoneal mast cells, human basophils, and human mast cell lines. Enhancement of histamine release by up to 41% in sensitized human basophils and two- to threefold increases in uterine mast cell histamine release have been documented, with effects observed across physiological concentrations (200–400 pg/ml E2). Environmental oestrogens with oestrogenic activity similarly potentiate mast cell degranulation, suggesting a receptor-mediated class effect rather than a molecule-specific phenomenon.

How it works

Oestradiol acts primarily through membrane-bound oestrogen receptor alpha (ERα) via a rapid non-genomic signalling pathway involving extracellular calcium influx, bypassing classical nuclear transcriptional mechanisms; ERβ is not detectably expressed on mast cells, and ERα antagonism with tamoxifen or calcium chelation blocks the degranulation response. E2 also upregulates mast cell tryptase expression, amplifying granule content and degranulation potential over longer timeframes, with progesterone acting synergistically to further enhance these effects.

---

Do hormonal contraceptives worsen or improve allergic rhinitis symptoms?

What the research says

Systemic hormonal contraceptives appear to worsen allergic rhinitis, with users showing approximately 32% increased odds of AR (adjusted OR 1.32, 95% CI: 1.20–1.44) compared to non-users, with both estrogen-containing and progestin-only formulations showing similar elevated risk. A smaller clinical study also found that oral contraceptive use intensified neurogenic symptoms such as sneezing during the pill cycle, though nasal congestion may be paradoxically reduced at certain timepoints. Notably, the increased AR risk contrasts with a potential protective effect of estrogen-containing contraceptives against chronic rhinosinusitis without nasal polyps, suggesting hormonal effects differ across rhinologic conditions.

How it works

Estrogen and progesterone receptors are present in nasal mucosal tissue, and exogenous sex hormones from contraceptives likely modulate local inflammatory responses, potentially promoting Th2-skewed immune activity or altering mast cell and vascular reactivity in ways that exacerbate IgE-mediated allergic responses. The divergence between synthetic contraceptive hormones and endogenous progesterone effects may be mechanistically important, as endogenous progesterone has been hypothesized to confer nasal protective effects that synthetic progestins do not replicate.

---

How does menopause affect allergy severity and new-onset sensitisation?

What the research says

Epidemiological data suggest that postmenopausal status is associated with decreased odds of allergic rhinitis compared to premenopausal status, with longer endogenous estrogen exposure linked to higher AR prevalence in postmenopausal women (Lee et al., 2019). However, the perimenopausal transition appears to be a period of potential allergy worsening or new-onset sensitisation due to erratic estrogen fluctuations, increased histamine release, and Th2 immune skewing, creating a paradox between perimenopause risk and postmenopause relative protection. Evidence on new-onset IgE-mediated sensitisation specifically attributable to menopause remains largely anecdotal or indirect.

How it works

Estrogen receptors on mast cells, basophils, and T-regulatory cells modulate immune tolerance; perimenopausal estrogen fluctuations promote mast cell hyperactivity and Th2 cytokine dominance (favouring IgE production), while postmenopausal estrogen depletion reduces pro-inflammatory signalling but also diminishes immune regulatory capacity. Concurrently, declining progesterone and disrupted histamine metabolism may compound airway and nasal mucosal reactivity.

---

Are there clinically significant sex differences in hayfever prevalence, severity, and treatment response?

What the research says

A clinically significant sex-based prevalence switch occurs at puberty: boys have higher allergic rhinitis prevalence in childhood (MFR ~1.21), which reverses during adolescence so that females predominate, though global adult differences are modest and non-significant (MFR ~0.96). Notable exceptions exist in Asian populations where male predominance persists into adulthood. Regarding severity, approximately 30–40% of allergic women report cyclical symptom worsening during perimenstrual phases, and women show higher susceptibility to systemic allergic reactions, while men paradoxically experience higher rates of fatal anaphylaxis.

How it works

Sex hormones are the primary biological driver: estrogen enhances Th2-polarized immune responses and promotes pro-inflammatory signaling, while testosterone appears to exert immunosuppressive and protective effects, explaining the post-pubertal shift toward female predominance. This hormonal immunomodulation operates through effects on dendritic cells, innate immune cells, and mast cell activity, creating sex-specific patterns of immune reactivity and airway inflammation.

---

Does pregnancy-related rhinitis overlap with or exacerbate allergic rhinitis?

What the research says

Pregnancy rhinitis and allergic rhinitis are pathophysiologically distinct conditions that frequently co-occur and can mutually exacerbate one another. Pregnancy rhinitis affects approximately 20% of pregnancies through hormonal and vascular mechanisms unrelated to IgE, while pre-existing allergic rhinitis follows a variable course during pregnancy—improving in roughly one-third of cases, remaining stable in one-third, and worsening in one-third. Women with pre-existing rhinitis (including allergic rhinitis) appear predisposed to developing pregnancy rhinitis, suggesting additive symptom burden when both conditions overlap.

How it works

Estrogen elevates nasal mucosal vascular permeability, upregulates histamine H1 receptor expression on epithelial and endothelial cells, and promotes eosinophil adhesion—effects that can amplify the pre-existing IgE-mediated inflammation of allergic rhinitis. Placental growth hormone variants and increased blood volume further contribute to nasal congestion, while female sex hormones also enhance IL-4 and IL-13 production from lymphocytes, potentially augmenting the Th2-skewed immune environment characteristic of allergic rhinitis.

---

In women with confirmed allergic rhinitis (n ≥ 200), do daily TNSS scores vary systematically across menstrual, follicular, ovulatory and luteal phases when controlled for daily pollen exposure?

What the research says

No published study has simultaneously examined daily TNSS variation across all four menstrual cycle phases in women with confirmed allergic rhinitis (n≥200) while controlling for daily pollen exposure, making a direct evidence-based answer impossible. Indirect evidence from smaller studies suggests nasal resistance and obstruction scores are higher during the ovulatory phase in healthy women (Babić et al., n=101), and atopic symptom questionnaires indicate premenstrual exacerbation of nasal symptoms in atopic women, but these use non-TNSS tools without allergen exposure control. Mechanistic evidence strongly supports biological plausibility for hormone-driven TNSS modulation, particularly via estrogen-mediated Th2 skewing and increased nasal mucosal vascularity, but the clinical magnitude, directionality by phase, and independence from pollen load remain unquantified in any adequately powered AR cohort.

How it works

Estrogen receptors (ERα and ERβ) expressed on nasal mucosal epithelium, vascular endothelium, submucosal glands, and mast cells mediate increased vascular permeability, glandular secretion, and Th2-biased immune responses (elevated IL-4, IL-5, IL-13, IgE), while progesterone contributes to systemic fluid retention and mucosal engorgement, collectively suggesting that pollen-triggered TNSS components—particularly congestion and rhinorrhea—could be amplified during high-estrogen (ovulatory) and high-progesterone (late luteal) phases even at equivalent allergen exposure.

---

Does the magnitude of cycle-phase variation in allergic rhinitis symptom severity correlate with serum oestradiol measured on the same day?

What the research says

No study has directly correlated day-specific serum estradiol measurements with validated allergic rhinitis symptom scores across the menstrual cycle, leaving the precise quantitative relationship unanswered. Indirect evidence from phase-level studies consistently supports a positive association: mid-cycle peaks in skin prick test reactivity correlate positively with serum estradiol (r≈0.3–0.5), nasal resistance increases approximately 10–30% during high-estrogen phases, and higher lifetime estrogen exposure associates with greater rhinitis prevalence. The available data therefore support a biologically plausible but incompletely characterised relationship between rising estradiol and amplified AR symptom magnitude.

How it works

Estradiol acts via genomic (ERα/ERβ) and non-genomic (GPER1) receptors expressed on nasal vascular endothelium, epithelium, mast cells, and eosinophils, promoting mucosal vasodilation, increased vascular permeability, upregulated FcεRI expression, and enhanced mast-cell degranulation in response to IgE cross-linking, collectively lowering the threshold for allergen-driven histamine and leukotriene release. The steepest E2 rise in the peri-ovulatory window thus temporally coincides with peak mast-cell sensitisation and nasal congestion reported in phase-level clinical studies.

---

Do hormonal-contraceptive users show flatter cycle-phase variation in allergic rhinitis symptoms than non-users, and if so, by what margin?

What the research says

Available evidence suggests that naturally cycling women with allergic rhinitis exhibit measurable menstrual phase variation in nasal symptoms and reactivity, with peaks typically around mid-cycle or the late luteal/perimenstrual phase, while combined oral contraceptive users show an attenuated version of this pattern—particularly for nasal obstruction. The most direct AR-specific evidence (Bonfils et al. 1999) indicates that OC users show less cycle-related variation in nasal airflow after allergen challenge, with the natural-cycle group showing approximately 1.5–2× greater obstruction amplitude between cycle phases, though OC users may paradoxically experience intensified sneezing near the end of the pill cycle. Cross-sectional population data (Dick et al. 2026; Bleier et al. 2024) confirm that systemic hormonal contraceptive users carry higher overall AR odds (OR ~1.3), suggesting that while phase-to-phase swings may be flattened, baseline disease burden is not reduced.

How it works

Nasal mucosal cells—including mast cells, eosinophils, epithelial cells, and sensory nerves—express estrogen receptors (ERα, ERβ) and progesterone receptors, making local allergic reactivity sensitive to cyclic hormonal fluctuations; estrogen at mid-cycle peaks enhances mast-cell degranulation, Th2 skewing, and IgE-mediated responses, while combined oral contraceptives suppress the mid-cycle estradiol surge and luteal progesterone swing, reducing peak allergen reactivity but substituting a relatively constant exogenous progestin and low-dose estrogen milieu that may maintain a Th2-biased environment and preserve or heighten neurogenic symptom pathways.